Waters and BioCity Debut New Open Access Analytical Laboratory in the BioHub at Alderley Park, UK

Laboratory provides access to cutting-edge analytical technologies which strengthen modern life and health sciences research

8 Mar 2016

Alex Waite

Editorial Assistant

Industry news

Waters Corporation and BioCity, the UK's largest bioscience incubator company, celebrated the opening of a new open access analytical laboratory.

Located in the BioHub at Alderley Park, the laboratory offers Waters’ state-of-the-art liquid chromatography (LC), mass spectrometry (MS) and informatics technologies, within a suite of analytical modules for scientists working in the pharmaceutical and life science industries.

Chancellor of the Exchequer, George Osborne stated, “This is more great news for Alderley Park and for Life Sciences in Cheshire. We are home to so many innovative and growing businesses in the sector and I was delighted to hear that BioCity Group and larger employers like Waters are helping to nurture new talent.”

“Scientists on-site now have access to state-of-the-art Waters’ capabilities through the open access facility,” said Rohit Khanna, Senior Vice President, Applied Technology. “The companies located at BioHub are engaged in breakthrough research and development. Close engagement with these companies provides Waters with a deeper insight into their needs and challenges.”

The laboratory will be resourced with many of Waters’ latest technology offerings, including ACQUITY^® QDa^®, ACQUITY H-Class™, ACQUITY UPC^2® and ACQUITY PDA Detector™, along with the expertise required to leverage the power of these instrumentation platforms. The laboratory also includes a nuclear magnetic resonance (NMR) system provided by Manchester Science Partnerships, the owners of Alderley Park.

“At Alderley Park, and indeed across the BioCity group, we are working with a growth formula that provides emerging and growing companies with access to everything they need to succeed - be it people, facilities, finance or technology,” said Dr. Glenn Crocker (MBE) CEO, BioCity Group. “The fact that our model and the work we are doing in partnership with Waters and MSP is recognized by the Chancellor is encouraging to hear. We are proud to be playing a leading role at the forefront of both the local and national economy.”

Related products

Request Quote for All Products

ACQUITY QDa Mass Detector
Waters
The ACQUITY QDa® Mass Detector gives you certainty above all else. You can minimize the risk of unexpected coelutions or components and confirms trace components with the analytical confidence of mass detection. The ACQUITY QDa® Detector is a mass detector built around the needs of analytical scientists for chromatographic analysis. Robust, reliable and requiring no sample adjustments, it just integrates with your current LC, ACQUITY UPLC, ACQUITY UPC2 and purification systems. You'll enhance the analytical value and productivity of each analysis, and you won't need to run all the additional assays or time-consuming alternative techniques or even wait for results from specialist labs that cost your laboratory productivity. With the ACQUITY QDa® Detector, you now have information-rich mass spectral data to complement data from your current Waters® optical detectors, including the ACQUITY UPLC PDA, TUV, ELS, and FLR detectors, as well as the ACQUITY UPC² PDA Detector. This mass spectral information integrates seamlessly into the same workflow; routinely giving you more complete separation characterization. Features: Intuitive operation More information from every sample Effortless integration Increased efficiency Resolving complexity Applications: Food & Environment Life Sciences and Pharmaceuticals Chemical
(20)
ACQUITY UPC² System
Waters
Convergence Chromatography with the ACQUITY UPC² System Bring streamlined workflow, expanded selectivity, and an orthogonal technique to your laboratory. Convergence chromatography (CC) is a broad-based, complementary analytical platform that is taking its place alongside of LC and GC as one of the three essential separation technologies for modern laboratory analysis. This technique provides another, reliable choice as an analytical platform that is orthogonal to reversed-phase LC (RPLC), while significantly streamlining the entire analytical workflow. In convergence chromatography, the separation is achieved by manipulating the density and composition of a supercritical fluid-based mobile phase. Because of the very high diffusivity of the mobile phase, can be achieved. Additionally, the diversity of stationary phase and mobile phase (co-solvent) options provides access to the largest selectivity space available to any separation technique. The ACQUITY UPC² System is a holistically designed UltraPerformance Convergence Chromatography (UPC²) system that utilizes liquid CO2 as the primary mobile phase. The system leverages the chromatographic principles and selectivity of normal-phase chromatography while providing the ease-of-use of RPLC, enabling you to address routine and complex separations challenges. ACQUITY UPC² System: Discover what's been missing from your analytical toolbox With the ACQUITY UPC² System, scientists can now separate, analyze, and understand compounds that have challenged all other LC and GC technologies including: Hydrophobic and chiral compounds Lipids Thermally-labile samples Polymers It's also the perfect complement to MS due to its low solvent load and high resolution, narrow peaks and fast separations. ACQUITY UPC² System Features: Compressed carbon dioxide (CO2), the primary mobile phase, is less costly and less toxic than liquid mobile phases or carrier gases. Variable volume injection delivers 0.5 µL to 10 µL as well as the ability to match column and injection volume with minimal sample loss and need to change loops. Higher throughput and productivity allows you to analyze more samples per day with faster re-equilibration of columns and shorter cycle times, increasing laboratory productivity. Co-solvent and column switching provides flexibility in method development for faster solvent screening and faster column screening.
(18)
ACQUITY UPLC H-Class PLUS System
Waters
Transform standard procedures into ultimate performance.
(44)
2998 Photodiode Array (PDA) Detector
Waters
The 2998 Photodiode Array (PDA) Detector offers advanced optical detection for Waters analytical HPLC, preparative HPLC, or LC/MS system solutions. Providing unprecedented trace impurity detection and quantitation, the 2998 PDA Detector’s integrated software and optics innovations deliver high chromatographic and spectral sensitivity. Enhanced software control provides flexibility for simultaneous 2D and 3D operation with either Empower™ or MassLynx™ Software. The Waters 2998 PDA Detector is designed for a range of laboratory applications, including trace impurity detection and quantification, compound identification and method development. Features of the Waters 2998 Photodiode Array PDA Detector: • Patented TaperSlit™ flow cell ensures high sensitivity while maintaining optimal spectral performance • Maximum signal-to-noise performance of <10 µAU • Simultaneous quantification of high- and low-level components within a single chromatographic separation for extended linear range • Flexible sampling rates for normal and fast LC separations from 1 to 80 Hz • Definitive compound identification & co-elution detection • Superior linear range with constant optical bandpass • Spectral exposure optimization to maximize the signal-to-noise across the entire wavelength range with a single Deuterium lamp • Thermal wander management for maximum baseline stability
(2)

Links

Waters Company website

Tags

AutosamplersSample PreparationLC-MSMass SpectrometryIncubatorsChem / BioinformaticsNanoLCLaboratory ManagementCell IncubationCollaborationLab EssentialsPharmaceuticals

ACQUITY UPC² System

Waters

Convergence Chromatography with the ACQUITY UPC² System Bring streamlined workflow, expanded selectivity, and an orthogonal technique to your laboratory. Convergence chromatography (CC) is a broad-based, complementary analytical platform that is taking its place alongside of LC and GC as one of the three essential separation technologies for modern laboratory analysis. This technique provides another, reliable choice as an analytical platform that is orthogonal to reversed-phase LC (RPLC), while significantly streamlining the entire analytical workflow. In convergence chromatography, the separation is achieved by manipulating the density and composition of a supercritical fluid-based mobile phase. Because of the very high diffusivity of the mobile phase, can be achieved. Additionally, the diversity of stationary phase and mobile phase (co-solvent) options provides access to the largest selectivity space available to any separation technique. The ACQUITY UPC² System is a holistically designed UltraPerformance Convergence Chromatography (UPC²) system that utilizes liquid CO2 as the primary mobile phase. The system leverages the chromatographic principles and selectivity of normal-phase chromatography while providing the ease-of-use of RPLC, enabling you to address routine and complex separations challenges. ACQUITY UPC² System: Discover what's been missing from your analytical toolbox With the ACQUITY UPC² System, scientists can now separate, analyze, and understand compounds that have challenged all other LC and GC technologies including: Hydrophobic and chiral compounds Lipids Thermally-labile samples Polymers It's also the perfect complement to MS due to its low solvent load and high resolution, narrow peaks and fast separations. ACQUITY UPC² System Features: Compressed carbon dioxide (CO2), the primary mobile phase, is less costly and less toxic than liquid mobile phases or carrier gases. Variable volume injection delivers 0.5 µL to 10 µL as well as the ability to match column and injection volume with minimal sample loss and need to change loops. Higher throughput and productivity allows you to analyze more samples per day with faster re-equilibration of columns and shorter cycle times, increasing laboratory productivity. Co-solvent and column switching provides flexibility in method development for faster solvent screening and faster column screening.

(18)

Waters and BioCity Debut New Open Access Analytical Laboratory in the BioHub at Alderley Park, UK

Industry news

Related products

ACQUITY QDa Mass Detector

ACQUITY UPC² System

ACQUITY UPLC H-Class PLUS System

2998 Photodiode Array (PDA) Detector

Links

Tags

Related articles

Shimadzu Scientific Instruments and Georgia Southern University launch research and education partnership

Complex lipid analysis challenges solved with bio-inert HPLC columns

Smart columns and open science drive PFAS breakthroughs

ACQUITY QDa Mass Detector

ACQUITY UPC² System

ACQUITY UPLC H-Class PLUS System

2998 Photodiode Array (PDA) Detector